My group aims to:
1. Develop and test vaccines for respiratory infections, particularly for children.
2. Understand why some individuals get more severe disease following respiratory infection.
To achieve these aims, we have developed a range of in vivo and in vitro models of infection and vaccination in early life, including RSV, Influenza, Pseudomonas aeruginosa, Staphylococcus aureus and non-typeable Haemophilus influenzae (ntHi).
I did my Post-Doc at Imperial College with Prof Peter Openshaw, working on RSV and for my PhD I worked on the development of a tetanus vaccine expressed in the chloroplasts of transgenic tobacco plants in the labs of Professors Peter Nixon and Gordon Dougan, also at Imperial College. I studied genetics at Downing College, Univeristy of Cambridge.
I blog about academic careers: and have written for Nature, Times Higher Education, The Guardian and NatureJobs.
I have experience of working with biotech companies to perform pre-clinical assesment of vaccines to RSV and influenza. This uses our well established infection models and we are open to further collaborations.
Members of Group
Helen Groves, PhD Student working on effect of infection on microbiome
David Busse, PhD Student working on ISG function
Dr Jacqueline McDonald (RA), worked on Vaccine safety
Dr Laura Lambert (RA), worked on RNA vaccines
Dr Ryan Russell (PhD Student), worked on Novel adjuvants
Dr Alex Badamchi Zadeh (PhD Student), co-supervised with Robin Shattock
Dr Griet van Roey (PhD Student), co supervised with Robin Shattock
Dr Matthew Siggins (RA), worked on ntHi vaccines
Dr Adam Walters (RA), worked on DNA vaccine constructs
Dr Simren Gill (PhD and Fellowship), worked on Pseudomonas aeruginosa
Ms Miko Zhong (MPhil), worked on neonatal immune response
Dr Katya Kinnear (PhD and Post Doc), worked on DNA vaccines with Touchlight Genetics
Ms Victoria Gould (RA), worked on IgA response to influenza
Dr Charanjit Singh (RA), worked on Ciliate derived vaccines
et al., 2018, Role of airway glucose in bacterial infections in patients with chronic obstructive pulmonary disease, Journal of Allergy and Clinical Immunology, Vol:142, ISSN:0091-6749, Pages:815-+
Tregoning J, 2018, How will you judge me if not by impact factor?, Nature, Vol:558, ISSN:0028-0836, Pages:345-345
et al., 2018, Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses, Molecular Therapy, Vol:26, ISSN:1525-0016, Pages:446-455
et al., 2018, Mouse Models of Influenza Infection with Circulating Strains to Test Seasonal Vaccine Efficacy, Frontiers in Immunology, Vol:9, ISSN:1664-3224
Tregoning J, 2018, From parade ground to PI., Science, Vol:359, Pages:362-362
et al., 2017, Inflammatory responses to influenza vaccination at the extremes of age, Immunology, Vol:151, ISSN:0019-2805, Pages:451-463
et al., 2017, Airway T cells protect against RSV infection in the absence of antibody, Mucosal Immunology, Vol:11, ISSN:1933-0219, Pages:249-256
Tregoning J, 2017, No researcher is too junior to fix science, Nature, Vol:545, ISSN:0028-0836, Pages:7-7
et al., 2016, Increased airway glucose increases airway bacterial load in hyperglycaemia, Scientific Reports, Vol:6, ISSN:2045-2322
et al., 2016, Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice, Journal of Virology, Vol:90, ISSN:0022-538X, Pages:4735-4744
et al., 2015, PHiD-CV induces anti-Protein D antibodies but does not augment pulmonary clearance of nontypeable Haemophilus influenzae in mice, Vaccine, Vol:33, ISSN:0264-410X, Pages:4954-4961
et al., 2015, Partial Attenuation of Respiratory Syncytial Virus with a Deletion of a Small Hydrophobic Gene Is Associated with Elevated Interleukin-1 beta Responses, Journal of Virology, Vol:89, ISSN:0022-538X, Pages:8974-8981
Kinnear E, Caproni LJ, Tregoning JS, 2015, A Comparison of Red Fluorescent Proteins to Model DNA Vaccine Expression by Whole Animal In Vivo Imaging, PLOS One, Vol:10, ISSN:1932-6203
et al., 2014, Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines, Gene Therapy, Vol:21, ISSN:1476-5462, Pages:645-652
et al., 2013, Neonatal antibody responses are attenuated by interferon-gamma produced by NK and T cells during RSV infection, Proceedings of the National Academy of Sciences of the United States of America, Vol:110, ISSN:0027-8424, Pages:5576-5581
Tregoning JS, Kinnear E, 2014, Using Plasmids as DNA Vaccines for Infectious Diseases.